127 related articles for article (PubMed ID: 33307284)
1. Glycation and acetylation sites on fibrinogen in plasma fibrin clot of patients with type 2 diabetes: Effects of low-dose acetylsalicylic acid.
Bryk AH; Zettl K; Wiśniewski JR; Undas A
Thromb Res; 2021 Feb; 198():93-98. PubMed ID: 33307284
[TBL] [Abstract][Full Text] [Related]
2. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease.
Neergaard-Petersen S; Hvas AM; Kristensen SD; Grove EL; Larsen SB; Phoenix F; Kurdee Z; Grant PJ; Ajjan RA
Thromb Haemost; 2014 Dec; 112(6):1142-50. PubMed ID: 25187394
[TBL] [Abstract][Full Text] [Related]
3. Effects of acetylsalicylic acid on increase of fibrin network porosity and the consequent upregulation of fibrinolysis.
He S; Bark N; Wang H; Svensson J; Blombäck M
J Cardiovasc Pharmacol; 2009 Jan; 53(1):24-9. PubMed ID: 19129740
[TBL] [Abstract][Full Text] [Related]
4. Plasma fibrin clot proteomics in healthy subjects: Relation to clot permeability and lysis time.
Ząbczyk M; Stachowicz A; Natorska J; Olszanecki R; Wiśniewski JR; Undas A
J Proteomics; 2019 Sep; 208():103487. PubMed ID: 31425886
[TBL] [Abstract][Full Text] [Related]
5. Fibrinogen Glycation and Presence of Glucose Impair Fibrin Polymerization-An In Vitro Study of Isolated Fibrinogen and Plasma from Patients with Diabetes Mellitus.
Luzak B; Boncler M; Kosmalski M; Mnich E; Stanczyk L; Przygodzki T; Watala C
Biomolecules; 2020 Jun; 10(6):. PubMed ID: 32517350
[TBL] [Abstract][Full Text] [Related]
6. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
7. Resistance of gammaA/gamma' fibrin clots to fibrinolysis.
Falls LA; Farrell DH
J Biol Chem; 1997 May; 272(22):14251-6. PubMed ID: 9162058
[TBL] [Abstract][Full Text] [Related]
8. BβArg448Lys polymorphism is associated with altered fibrin clot structure and fibrinolysis in type 2 diabetes.
Greenhalgh KA; Strachan MW; Alzahrani S; Baxter PD; Standeven KF; Storey RF; Ariens RA; Grant PJ; Price JF; Ajjan RA
Thromb Haemost; 2017 Jan; 117(2):295-302. PubMed ID: 27929198
[TBL] [Abstract][Full Text] [Related]
9. Interaction of glycated and acetylated human α2-antiplasmin with fibrin clots.
Bryk AH; Satała D; Natorska J; Rąpała-Kozik M; Undas A
Blood Coagul Fibrinolysis; 2020 Sep; 31(6):393-396. PubMed ID: 32815915
[TBL] [Abstract][Full Text] [Related]
10. Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a concentration dependent manner: a mass spectrometric and isotope labeling study.
Svensson J; Bergman AC; Adamson U; Blombäck M; Wallén H; Jörneskog G
Biochem Biophys Res Commun; 2012 May; 421(2):335-42. PubMed ID: 22507986
[TBL] [Abstract][Full Text] [Related]
11. Plasma fibrin clot properties and cardiovascular mortality in patients with type 2 diabetes: a long-term follow-up study.
Bryk AH; Konieczyńska M; Polak M; Plicner D; Bochenek M; Undas A
Cardiovasc Diabetol; 2021 Feb; 20(1):47. PubMed ID: 33602240
[TBL] [Abstract][Full Text] [Related]
12. Plasma fibrin clot proteomics in patients with acute pulmonary embolism: Association with clot properties.
Bryk AH; Natorska J; Ząbczyk M; Zettl K; Wiśniewski JR; Undas A
J Proteomics; 2020 Oct; 229():103946. PubMed ID: 32810596
[TBL] [Abstract][Full Text] [Related]
13. Identification of glycated and acetylated lysine residues in human α2-antiplasmin.
Bryk AH; Cysewski D; Dadlez M; Undas A
Biochem Biophys Res Commun; 2020 Jan; 521(1):19-23. PubMed ID: 31653347
[TBL] [Abstract][Full Text] [Related]
14. The myeloperoxidase product, hypochlorous acid, reduces thrombus formation under flow and attenuates clot retraction and fibrinolysis in human blood.
Misztal T; Golaszewska A; Tomasiak-Lozowska MM; Iwanicka M; Marcinczyk N; Leszczynska A; Chabielska E; Rusak T
Free Radic Biol Med; 2019 Sep; 141():426-437. PubMed ID: 31279970
[TBL] [Abstract][Full Text] [Related]
15. Sex-specific alteration to α2-antiplasmin incorporation in patients with type 2 diabetes.
Bryk AH; Siudut J; Broniatowska E; Bagoly Z; Baráth B; Katona É; Undas A
Thromb Res; 2020 Jan; 185():55-62. PubMed ID: 31770688
[TBL] [Abstract][Full Text] [Related]
16. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3.
Hess K; Alzahrani SH; Mathai M; Schroeder V; Carter AM; Howell G; Koko T; Strachan MW; Price JF; Smith KA; Grant PJ; Ajjan RA
Diabetologia; 2012 Apr; 55(4):1103-13. PubMed ID: 21918806
[TBL] [Abstract][Full Text] [Related]
17. Impact of fibrinogen carbamylation on fibrin clot formation and stability.
Binder V; Bergum B; Jaisson S; Gillery P; Scavenius C; Spriet E; Nyhaug AK; Roberts HM; Chapple ILC; Hellvard A; Delaleu N; Mydel P
Thromb Haemost; 2017 May; 117(5):899-910. PubMed ID: 28382370
[TBL] [Abstract][Full Text] [Related]
18. Glycaemic control improves fibrin network characteristics in type 2 diabetes - a purified fibrinogen model.
Pieters M; Covic N; van der Westhuizen FH; Nagaswami C; Baras Y; Toit Loots D; Jerling JC; Elgar D; Edmondson KS; van Zyl DG; Rheeder P; Weisel JW
Thromb Haemost; 2008 Apr; 99(4):691-700. PubMed ID: 18392327
[TBL] [Abstract][Full Text] [Related]
19. Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis: A Systematic Review.
de Vries JJ; Snoek CJM; Rijken DC; de Maat MPM
Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):554-569. PubMed ID: 31914791
[TBL] [Abstract][Full Text] [Related]
20. The structure and biological features of fibrinogen and fibrin.
Mosesson MW; Siebenlist KR; Meh DA
Ann N Y Acad Sci; 2001; 936():11-30. PubMed ID: 11460466
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
